Literature DB >> 3690140

Plasma oxipurinol concentrations during allopurinol therapy.

B T Emmerson1, R B Gordon, M Cross, D B Thomson.   

Abstract

The plasma concentrations of oxipurinol, the chief metabolite of allopurinol, were studied in 66 patients with gout in whom the dose of allopurinol varied between 100 and 400 mg per day. Renal function ranged from normal to moderately impaired. Plasma oxipurinol concentrations correlated directly with both allopurinol dosage and with renal glomerular function as reflected by the plasma creatinine concentration. Plasma oxipurinol concentrations between 30 and 100 mumol/l were generally effective in controlling hyperuricaemia. However, oxipurinol concentrations usually rose above this range if the daily dose of allopurinol exceeded 300 mg in patients with plasma creatinine concentrations of 0.2 mmol/l or more. In patients with normal renal function, a rise of the plasma xanthine concentration to between 6 and 9 mumol/l suggested a satisfactory degree of xanthine oxidase inhibition. These measurements are particularly useful in patients who are still hyperuricaemic despite the usual doses of allopurinol.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3690140     DOI: 10.1093/rheumatology/26.6.445

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  22 in total

1.  T-1032, a cyclic GMP phosphodiesterase-5 inhibitor, acutely blocks physiologic insulin-mediated muscle haemodynamic effects and glucose uptake in vivo.

Authors:  Hema Mahajan; Stephen M Richards; Stephen Rattigan; Michael G Clark
Journal:  Br J Pharmacol       Date:  2003-10-27       Impact factor: 8.739

2.  Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy.

Authors:  G M Peterson; R R Boyle; H W Francis; N W Oliver; J Paterson; R J von Witt; G R Taylor
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  The pharmacokinetics of oxypurinol in people with gout.

Authors:  Sophie L Stocker; Andrew J McLachlan; Radojka M Savic; Carl M Kirkpatrick; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

4.  Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.

Authors:  R O Day; J O Miners; D J Birkett; A Whitehead; D Naidoo; J Hayes; E Savdie
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

5.  Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol.

Authors:  R O Day; J Miners; D J Birkett; G G Graham; A Whitehead
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

6.  Acute glucosamine-induced insulin resistance in muscle in vivo is associated with impaired capillary recruitment.

Authors:  M G Wallis; M E Smith; C M Kolka; L Zhang; S M Richards; S Rattigan; M G Clark
Journal:  Diabetologia       Date:  2005-07-30       Impact factor: 10.122

Review 7.  Gout: optimizing treatment to achieve a disease cure.

Authors:  José Antonio Bernal; Neus Quilis; Mariano Andrés; Francisca Sivera; Eliseo Pascual
Journal:  Ther Adv Chronic Dis       Date:  2016-01-12       Impact factor: 5.091

8.  1-Methylxanthine derived from theophylline as an in vivo biochemical probe of allopurinol effect.

Authors:  D J Birkett; J O Miners; R O Day
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

Review 9.  Allopurinol hypersensitivity: investigating the cause and minimizing the risk.

Authors:  Lisa K Stamp; Richard O Day; James Yun
Journal:  Nat Rev Rheumatol       Date:  2015-09-29       Impact factor: 20.543

Review 10.  Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Authors:  Richard O Day; Garry G Graham; Mark Hicks; Andrew J McLachlan; Sophie L Stocker; Kenneth M Williams
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.